- Leadership
- Program
- 2023 Program at a Glance
- 2023 Head & Neck Oncology Session
- 2023 GI Cancer Session
- 2023 Immuno Oncology Session
- 2023 Breast Imaging / Breast Surgical
- 2023 Breast Cancer Session
- 2023 Lung Cancer Session
- 2023 Uro Oncology Session
- 2023 Oncology Nursing Session
- 2023 Oncology Nutrition Session
- 2023 Palliative Care Session
- 2023 APMEA MTB Session
- 2023 Congress E-Brochure
- Speakers
- Partners
- Media
- Contact
- Register Now
- In Conversation
- Day 3 Access
- Journal Club
- About
- Upcoming JC
- Past Archived JC's
- 2023
- February 13th Edition
- February 22nd Edition
- February 28th Edition
- March 6th Edition
- March 20th Edition
- April 17th Edition
- May 08th Edition
- May 17th Edition
- May 29th Edition
- June 12th Edition
- June 22nd Edition
- June 23rd Edition
- August 14th Edition
- September 7th Edition
- September 18th Edition
- October 16th Edition
- November 23rd Edition
- 2022
- 2021
- 2020
- 2023
- In Conversation Series
- DOWNLOAD CME

Tobias Arkenau
Medical Director, UK
Dr Hendrik-Tobias Arkenau is the founding Medical Director of Sarah Cannon Research Institute UK, and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the Hospital Corporation of America International Cancer Service Line.Dr Arkenau has vast experience in Early Oncology Clinical Drug Development with a special interest in gastrointestinal cancer and melanoma. He received his medical degree in 2000 at the Medical School Hanover, Germany, and completed his internship and specialist training in oncology in 2007. As part of SCRI’s collaboration with University College London (UCL), Dr Arkenau is appointed as a Professorial Research Associate on UCLs faculty and he holds an Honorary Consultant post with UCL Hospitals.
